DadFinStart your free week
DadFin › Stocks › Healthcare › CSTL

Castle Biosciences, Inc. (CSTL) stock score

Healthcare · Diagnostics & Research · United States

$34.42 ▲ +2.11% today

63.2
Dad Score, out of 100
middling

Castle Biosciences, Inc. (CSTL) is a Diagnostics & Research company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 63.2 out of 100 on the Dad Score, a middling reading that places the business ahead of 63% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #316 of 974. Its strongest axis is price action; its weakest is growth.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Average
Growth
Below average
Price action
Above average
Risk
Average
Conviction
Average
Liquidity
Average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-37.9×
Dividend yield0.00%
Return on capital-5.8%
Operating margin-3.0%
Revenue growth (YoY)+3.7%
FCF yield2.9%
Net debt / EBITDA3.00×
Piotroski F-Score3 / 9
52-week change+52.5%
Market cap$1.1B
Next earningsNov 2, 2026

What subscribers see on CSTL

Start your free weekSubscriber? Open the full research →

Diagnostics & Research peers

StockCompanyDad ScoreBandMarket cap
TMOThermo Fisher Scientific Inc.77.0good$242.1B
DHRDanaher Corporation79.6good$150.5B
NTRANatera, Inc.86.1strong$59.1B
AAgilent Technologies, Inc.79.9good$47.3B
IQVIQVIA Holdings Inc.82.3good$42.5B
WATWaters Corporation78.8good$41.7B
ILMNIllumina, Inc.35.1weak$41.2B
IDXXIDEXX Laboratories, Inc.90.1strong$40.9B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.